InterCure Ltd. (INCR)
USD 1.6
(3.23%)
USD 1.6
(3.23%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -41.56 Million ILS | -178.72% |
| 2022 | 52.8 Million ILS | 87.32% |
| 2021 | 28.18 Million ILS | 2046.69% |
| 2020 | -1.44 Million ILS | 98.19% |
| 2019 | -80.13 Million ILS | -654.43% |
| 2018 | -10.62 Million ILS | -166.68% |
| 2017 | -3.98 Million ILS | -430.82% |
| 2016 | 1.2 Million ILS | 147.97% |
| 2015 | -2.51 Million ILS | -193.97% |
| 2014 | 2.67 Million ILS | 237.96% |
| 2013 | -1.93 Million ILS | 10.95% |
| 2012 | -2.17 Million ILS | -20.52% |
| 2011 | -1.8 Million ILS | 63.94% |
| 2010 | -5 Million ILS | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 5.25 Million ILS | 119.71% |
| 2024 Q2 | 5.25 Million ILS | 0.0% |
| 2023 Q1 | 5.94 Million ILS | 478.31% |
| 2023 Q2 | 5.82 Million ILS | -2.14% |
| 2023 Q4 | -26.66 Million ILS | -301.55% |
| 2023 Q3 | -6.64 Million ILS | -214.11% |
| 2023 FY | -41.56 Million ILS | -178.72% |
| 2022 Q3 | 16.18 Million ILS | -9.72% |
| 2022 Q2 | 17.92 Million ILS | -10.32% |
| 2022 Q1 | 19.98 Million ILS | 120.79% |
| 2022 FY | 52.8 Million ILS | 87.32% |
| 2022 Q4 | -1.57 Million ILS | -109.71% |
| 2021 Q1 | 5.11 Million ILS | -31.37% |
| 2021 FY | 28.18 Million ILS | 2046.69% |
| 2021 Q4 | 9.05 Million ILS | 99.36% |
| 2021 Q2 | 8.87 Million ILS | 73.55% |
| 2021 Q3 | 4.54 Million ILS | -48.86% |
| 2020 Q3 | 2.37 Million ILS | 380.64% |
| 2020 FY | -1.44 Million ILS | 98.19% |
| 2020 Q1 | -47.38 Million ILS | -251.59% |
| 2020 Q2 | -847 Thousand ILS | 98.21% |
| 2020 Q4 | 7.45 Million ILS | 213.59% |
| 2019 Q3 | -14.43 Million ILS | -40.19% |
| 2019 FY | -80.13 Million ILS | -654.43% |
| 2019 Q1 | 37.68 Million ILS | 862.64% |
| 2019 Q2 | -10.29 Million ILS | -127.32% |
| 2019 Q4 | -13.47 Million ILS | 6.6% |
| 2018 FY | -10.62 Million ILS | -166.68% |
| 2018 Q4 | -4.94 Million ILS | 0.0% |
| 2018 Q3 | -4.94 Million ILS | -3821.43% |
| 2018 Q2 | -126 Thousand ILS | 0.0% |
| 2018 Q1 | -126 Thousand ILS | 63.27% |
| 2017 Q4 | -343.06 Thousand ILS | -0.0% |
| 2017 Q3 | -343.06 Thousand ILS | -50.15% |
| 2017 Q1 | -237.23 Thousand ILS | -238.32% |
| 2017 Q2 | -228.48 Thousand ILS | 3.69% |
| 2017 FY | -3.98 Million ILS | -430.82% |
| 2016 Q2 | -593.81 Thousand ILS | -145.93% |
| 2016 Q1 | 1.29 Million ILS | 259.87% |
| 2016 FY | 1.2 Million ILS | 147.97% |
| 2016 Q4 | 171.5 Thousand ILS | -47.49% |
| 2016 Q3 | 326.63 Thousand ILS | 155.01% |
| 2015 FY | -2.51 Million ILS | -193.97% |
| 2015 Q3 | -1.07 Million ILS | -279.77% |
| 2015 Q2 | -283.47 Thousand ILS | 14.71% |
| 2015 Q1 | -332.37 Thousand ILS | -106.94% |
| 2015 Q4 | -808.74 Thousand ILS | 24.88% |
| 2014 Q3 | -427.52 Thousand ILS | 59.83% |
| 2014 Q2 | -1.06 Million ILS | -105.33% |
| 2014 Q1 | -518.26 Thousand ILS | -141.11% |
| 2014 FY | 2.67 Million ILS | 237.96% |
| 2014 Q4 | 4.78 Million ILS | 1219.64% |
| 2013 Q4 | 1.26 Million ILS | 332.45% |
| 2013 FY | -1.93 Million ILS | 10.95% |
| 2013 Q3 | -542.33 Thousand ILS | 64.18% |
| 2013 Q2 | -1.51 Million ILS | -25.95% |
| 2013 Q1 | -1.2 Million ILS | 5.52% |
| 2012 Q1 | -300.9 Thousand ILS | 33.28% |
| 2012 Q2 | -571.31 Thousand ILS | -89.87% |
| 2012 Q3 | -7878.04 ILS | 98.62% |
| 2012 Q4 | -1.27 Million ILS | -16049.72% |
| 2012 FY | -2.17 Million ILS | -20.52% |
| 2011 FY | -1.8 Million ILS | 63.94% |
| 2011 Q3 | -451.01 Thousand ILS | 0.0% |
| 2011 Q1 | -451.01 Thousand ILS | 63.94% |
| 2011 Q2 | -451.01 Thousand ILS | 0.0% |
| 2011 Q4 | -451.01 Thousand ILS | 0.0% |
| 2010 Q4 | -1.25 Million ILS | 0.0% |
| 2010 Q1 | -1.25 Million ILS | 0.0% |
| 2010 Q3 | -1.25 Million ILS | 0.0% |
| 2010 FY | -5 Million ILS | 0.0% |
| 2010 Q2 | -1.25 Million ILS | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Esperion Therapeutics, Inc. | -155.56 Million USD | 73.28% |
| Theratechnologies Inc. | -10.62 Million USD | -291.145% |
| Safety Shot Inc | -12.18 Million USD | -241.156% |
| Cosmos Health Inc. | -21.83 Million USD | -90.402% |
| Cronos Group Inc. | -81.37 Million USD | 48.919% |
| Ironwood Pharmaceuticals, Inc. | 209.03 Million USD | 119.885% |
| Kala Pharmaceuticals, Inc. | -39.15 Million USD | -6.166% |
| Organogenesis Holdings Inc. | 12.52 Million USD | 431.872% |
| Universe Pharmaceuticals INC | -3.52 Million USD | -1078.613% |
| ProPhase Labs, Inc. | -21.61 Million USD | -92.324% |
| Sonoma Pharmaceuticals, Inc. | -4.7 Million USD | -784.216% |
| Dynavax Technologies Corporation | -37.02 Million USD | -12.258% |
| Radius Health, Inc. | -3.92 Million USD | -959.032% |
| China SXT Pharmaceuticals, Inc. | -2.51 Million USD | -1552.621% |
| Alvotech | -354.86 Million USD | 88.286% |
| Sunshine Biopharma, Inc. | -4.78 Million USD | -768.64% |
| Alpha Teknova, Inc. | -35.56 Million USD | -16.883% |
| Intra-Cellular Therapies, Inc. | -159.38 Million USD | 73.92% |
| SCYNEXIS, Inc. | 72.66 Million USD | 157.2% |
| Harrow Health, Inc. | 580 Thousand USD | 7266.724% |
| Biofrontera Inc. | -22.67 Million USD | -83.3% |
| DURECT Corporation | -36.88 Million USD | -12.697% |
| Supernus Pharmaceuticals, Inc. | -5.26 Million USD | -688.897% |
| ANI Pharmaceuticals, Inc. | 46.97 Million USD | 188.495% |
| OptiNose, Inc. | -22.74 Million USD | -82.728% |
| RedHill Biopharma Ltd. | 12.63 Million USD | 429.061% |
| Aquestive Therapeutics, Inc. | -15.1 Million USD | -175.242% |
| Cumberland Pharmaceuticals Inc. | -6.21 Million USD | -569.268% |
| SIGA Technologies, Inc. | 83.62 Million USD | 149.709% |
| Lifecore Biomedical, Inc. | 9.33 Million USD | 545.472% |
| Shineco, Inc. | -17.06 Million USD | -143.568% |
| Phibro Animal Health Corporation | 53.31 Million USD | 177.965% |
| Procaps Group S.A. | 52.32 Million USD | 179.442% |
| TherapeuticsMD, Inc. | -8.52 Million USD | -387.704% |
| Regencell Bioscience Holdings Limited | -4.73 Million USD | -777.547% |
| Viatris Inc. | 766.2 Million USD | 105.425% |
| Sunshine Biopharma, Inc. | -4.78 Million USD | -768.64% |
| Rockwell Medical, Inc. | -6.67 Million USD | -523.193% |
| Incannex Healthcare Limited | -30.04 Million USD | -38.368% |
| Aytu BioPharma, Inc. | -5.25 Million USD | -691.15% |
| Tilray Brands, Inc. | -174.74 Million USD | 76.213% |
| Collegium Pharmaceutical, Inc. | 166.96 Million USD | 124.896% |
| PetIQ, Inc. | 60.01 Million USD | 169.261% |
| Silver Spike Investment Corp. | 7.34 Million USD | 666.299% |
| Neurocrine Biosciences, Inc. | 250.9 Million USD | 116.567% |
| Journey Medical Corporation | -2.07 Million USD | -1905.162% |
| Alimera Sciences, Inc. | -1.47 Million USD | -2725.765% |
| Petros Pharmaceuticals, Inc. | -13.61 Million USD | -205.25% |
| Assertio Holdings, Inc. | -243.53 Million USD | 82.932% |
| Shuttle Pharmaceuticals Holdings, Inc. | -5.89 Million USD | -605.437% |
| Embecta Corp. | 221.5 Million USD | 118.766% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | -107.316% |
| Procaps Group, S.A. | 38.97 Million USD | 206.656% |
| PainReform Ltd. | -9.58 Million USD | -333.712% |
| Avadel Pharmaceuticals plc | -137.84 Million USD | 69.846% |
| Hempacco Co., Inc. | -8.81 Million USD | -371.694% |
| Talphera, Inc. | -16.88 Million USD | -146.119% |
| Pacira BioSciences, Inc. | 87.67 Million USD | 147.41% |
| Alvotech | -354.86 Million USD | 88.286% |
| Lantheus Holdings, Inc. | 364.64 Million USD | 111.399% |
| Kamada Ltd. | 10.06 Million USD | 513.027% |
| Indivior PLC | -4 Million USD | -939.175% |
| Currenc Group, Inc. | -6.64 Million USD | -525.464% |
| Evoke Pharma, Inc. | -7.43 Million USD | -459.381% |
| Flora Growth Corp. | -50.35 Million USD | 17.45% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | -107.316% |
| Evolus, Inc. | -49.23 Million USD | 15.571% |
| HUTCHMED (China) Limited | 18.37 Million USD | 326.215% |
| Amphastar Pharmaceuticals, Inc. | 196.98 Million USD | 121.101% |
| Akanda Corp. | -10.05 Million USD | -313.545% |